A case report of a solitary pancreatic metastasis of an adrenocortical carcinoma

Johannes Baur1*, Ulla Schedelbeck2, Alina Pulzer4, Christina Bluemel3, Vanessa Wild5,6, Martin Fassnacht4,5 and U. Steger1

Abstract

Background: Solitary metastases to the pancreas are rare. Therefore the value of resection in curative intention remains unclear. In the literature there are several promising reports about resection of solitary metastasis to the pancreas mainly of renal origin.

Case presentation: Here we report for the first time on the surgical therapy of a 1.5 cm solitary pancreatic metastasis of an adrenocortical carcinoma. The metastasis occurred almost 6 years after resection of the primary tumor. A partial pancreatoduodenectomy was performed and postoperatively adjuvant mitotane treatment was initiated. During the follow-up of 3 years after surgery no evidence of tumor recurrence occurred.

Conclusion: Resection of pancreatic tumors should be considered, even if the mass is suspicious for metastatic disease including recurrence of adrenocortical cancer.

Keywords: Adrenocortical Carcinoma, Metastases to pancreas, Surgical treatment

Background

Adrenocortical carcinoma (ACC) is a rare malignant tumor with an estimated incidence of 1 to 2 cases per million population [1]. The occurrence has a first peak in childhood and a second in the fourth and fifth decade of life. The majority of ACC are sporadic. But in some cases ACC is part of hereditary syndromes like Li-Fraumeni syndrome, Beckwith-Wiedeman syndrome, multiple endocrine neoplasia (MEN) 1, congenital adrenal hyperplasia or familial polypsis coli [2]. Therapy and prognosis strongly depend on the European Network for the Study of Adrenal Tumours (ENSAT) classification [3]. In localized disease, surgery is treatment of choice [4], whereas in advanced disease mitotane alone or in combination with cytotoxic drugs is standard of care [5]. According to the German ACC register, 5-year-survival rates are 84 %, 63 %, 51 % and 15 % for Stage I, II, III and IV respectively [6]. Management of recurrent disease is not standardized [5], but recent retrospective studies suggest that surgery is of benefit in selected cases [7].

Metastatic involvement of pancreas due to any primary malignant tumor is rare and represents about 2 % of all pancreatic tumors. Most of these patients show diffuse distant metastases of their primary tumor [8] with no opportunity of surgical treatment.

Here, we present a case of recurrent ACC with a solitary pancreatic metastasis 6 years after resection of the primary tumor.

Case presentation

A 45-year-old woman was first diagnosed in 2006 with ACC showing typical signs of Cushing’s syndrome with consecutive increase of weight and body hair, acne, therapy-refractory arterial hypertension and decrease of physical working capacity. Hormonal work-up revealed elevated cortisol levels basal and after dexamethasone suppression, as well as elevated dehydroepiandrosterone sulphate (DHEA-S) and androgen levels. CT scan showed a 4.7 × 5.2 × 4.5 cm sized mass of the left adrenal gland with venous contrast enhancement suspicious for adrenocortical carcinoma (Fig. 1).

The patient underwent conventional resection of the left adrenal gland and lymphadenectomy. Pathological study of the resected tissue was performed by two independent pathologists. The tumor presented a solid growth pattern with some fibrous bands and small areas of necrosis. Tumor cells appeared monomorphic with small nuclei.
and condensed chromatin. The rate of mitosis was under 1 in 10 high power fields. Interestingly there were large amounts of myelolipomatosis metaplastic areas. All three classic scoring systems showed results still within the value range for benign lesions. However, a high Ki-67 expression of 20 % led to the diagnosis of an adrenocortical carcinoma (ENSAT stage II). Due to a good differentiation, no adjuvant mitotane therapy has been performed. Though the patient underwent follow-up examinations periodically, including hormonal work-up and CT or MR imaging performed initially every 3 months and eventually every 6 months after a 2-year-recurrence-free survival.

Sixty-six months after surgical treatment MR imaging showed a new hyperperfused mass in the head of the pancreas with progression of size in the following studies as well as a high FDG-uptake in positron emission tomography (Fig. 1). Thus, the mass was highly suspicious of malignancy and resection was recommended by interdisciplinary consensus.

The patient underwent pylorus preserving partial pancreaticoduodenectomy. Postoperatively the patient developed a pancreatic fistula with an intraabdominal abscess formation, which had to be drained interventionally on day 10 after surgery. The drain could be removed on day 24 after surgery.

Histological and immunohistochemical examination of the resected tissue showed a 1.5 cm sized well differentiated tumor with solid growth pattern (Fig. 2a). Tumor cells presented monomorphic with eosinophilic cytoplasm and unremarkable nuclei. The metastasis stained positive for synaptophysin, Melan A and steroidogenic factor 1 (SF-1) in consistency with the diagnosis as a metastasis of the adrenocortical carcinoma (Fig. 2b) with a Ki-67 expression in 10 % of tumor cells. There were no signs of a primary pancreatic carcinoma as the tumor cells stained negative for pan cytokeratine (pan-ck) (Fig. 2c). In addition, pathological examination by the reference pathologist of the German ACC study group was performed and confirmed the correlation between the ACC primary tumor and the unusual site of metastasis.

According to interdisciplinary consensus an adjuvant mitotane therapy was initiated after the tumor resection and is still ongoing. During follow-up, including endocrine and imaging work-up every 3 months now for more than 3 years, there is no evidence of recurrence (Time axis see Table 1).

**Literature review**

A literature review has been performed to identify the distribution of different tumor entities of solitary metastases inside the pancreas. A PubMed search for studies or case reports dealing with “metastases to pancreas” was performed. Articles were included in this review if 10 or more patients were investigated retrospectively or prospectively, patients suffered of metastases to pancreas (no infiltrative involvement) and only the pancreas was affected by metastases, patients received resection of pancreas metastases in curative intension and different tumor entities were included in each study. Four retrospective studies [9–12] summerized in Table 2 met the
inclusion criteria with a total of 92 patients. Median age of patients ranged from 59 to 64 years. Most frequent origin of pancreatic metastases was the kidney in 46% of the cases followed by melanoma in about 10% of the cases. Rectal and Colon carcinomas were involved in only 5 cases. One “non-pancreatic endocrine tumor” was reported but not specified in more detail [12]. Here, the distribution of metastatic origin is different to other literature reviews, where the proportion of renal cell carcinomas range between 60 and 70% [8]. This is caused by the exclusion of studies intending to investigate a single tumor entity metastatic to the pancreas (mostly renal cell carcinomas). Median survival after curative resection of pancreatic metastases was 2.2 to 4.3 years. 5-year-survival ranged between 36 % and 61 %.

**Discussion**
Solitary metastases to the pancreas are rare. Only 1.3% of patients undergoing pancreatic resection present a solitary metastasis of a primary solid tumor [12]. In our literature review singular metastasis to the pancreas was most frequent of renal origin (46% of cases). The value of resection in curative intention remains unclear. As our literature review revealed, 5-year-survival may range between 36 % and 61 % if different tumor entities are taken together. Certain metastatic tumor entities even show better survival rates after curative resection compared to primary pancreatic carcinomas. In case of a singular pancreatic metastasis of renal cell carcinoma a 5-year-survival between 66 % and 79 % can be achieved by curative resection of pancreatic metastasis [8, 13].

**Table 1** Time axis

| Year       | Event                                                                 |
|------------|----------------------------------------------------------------------|
| 2006       | Conventional left-side Adrenalectomie of an Adrenocortical Carcinoma (stadium II, diameter 7 cm) |
| 2006 - 2012 | Unsuspicious follow-up in periodically performed cross-sectional studies |
| 02/2012    | Detection of a pancreatic mass suspicious for malignancy in PET       |
| 03/2012    | Pylorus preserving partial pancreaticoduodenectomy Histological and immunohistochemic examination showed a 1.5 cm sized well differentiated metastasis of the adrenocortical carcinoma |
| Till present date | Mitotane Therapy, unsuspicious follow-up in periodically performed cross-sectional studies and hormonal work-up |

**Fig. 2** Histology of pancreatic mass (a) metastasis with adjacent pancreatic tissue (*) (HE stain, 20x) (b) ACC metastasis with nuclear positive staining pattern for SF-1 (SF1, 40x) (c) ACC metastasis with positive cytoplasmic staining for Synaptophysin (d) ACC metastasis with positive cytoplasmic staining for Inhibin [E] ACC metastasis is negative for pan-ck (AE1/3, 20x), the pancreatic acini stain positive for pan-ck.
Table 2 Literature review

| Author (Year)           | Years observed | No. of patients | Median age | Median survival (y) | 5-year survival (y) | RCC  | Melanoma | Gall bladder | Sarcoma | Colon | Ovar | Lung | Breast | Others* |
|-------------------------|----------------|-----------------|------------|---------------------|---------------------|------|----------|--------------|---------|-------|------|------|--------|---------|
| Reddy el al. (2008)     | 1970–2007      | 49              | 60         | 3.7                 | 36 %                | 21   | 3(6.1)   | 6 (12.2)     | 4 (8.2) | 2 (4.1) | 4 (8.2) | 1 (2.0) | 4 (8.1) |
| Bahra et al. (2008)     | 1989–2007      | 20              | 62         | not reached         | 61 %                | 9    | 1 (5.0)  | 1 (5.0)      | 2 (10.0) | 1 (5.0) | -     | -     | -      | 6 (12.2) |
| Eidt et al. (2007)      | 1993–2005      | 12              | 64         | 4.3                 | not reported        | 7    | 4(33.1)  | -            | -       | 1 (8.3) | -     | -     | -      | -       |
| Crippa et al. (2006)    | 1994–2005      | 11              | 59         | 2.2                 | 48 %                | 5    | 1(9.1)   | -            | -       | 1 (9.1) | 1 (9.1) | 3 (27.3) | -       |
|                         |                | 92              |            |                     |                     | 42   | 9(9.8)   | 7(7.6)       | 6(6.5)  | 5(5.4) | 4(4.3) | 4(4.3) | 1(10.9) |

*RCC Renal cell carcinoma
*Schwannoma (reported twice); Seminoma, Teratocarcinoma, Hepatocellular Carcinoma, Langerhans cell histiocytosis, esophagus, mesenchymal gastric tumor, non-pancreatic endocrine tumor (not specified), GIST (each one case reported)
Here we report for the first time a case of a solitary pancreatic metastasis of an adrenocortical carcinoma. ACC is one of the most aggressive endocrine tumors known so far. Resection of recurrent tumor is recommended in selected case (e.g. when the disease-free interval exceeds 12 months and complete resection seems to be feasible) [7]. In our case, the metastasis occurred almost 6 years after resection of a very well differentiated primary tumor and a R0 resection could be performed. Although known to improve recurrence-free survival after resection of primary tumor [14], it remains unclear if adjuvant mitotane therapy would have prevented recurrence of ACC. However, the patient would have suffered from mitotane side effects like adrenocortical insufficiency. As the patient is now again free of disease for more than 3 years, surgical approach to treat solitary pancreatic ACC metastasis was most likely of great benefit to her.

Conclusion
In conclusion, resection of pancreatic tumors should be considered, even if the mass is suspicious for metastatic disease including recurrence of adrenocortical cancer.

Consent
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

Abbreviations
ACC: Adrenocortical carcinoma; ENSAT: European Network of the Study of Adrenal Tumours; DHEA-S: Dehydroepiandrosterone sulphate; SF-1: Steroidogenic factor 1; pan-ck: Pancreatic cytoceratine.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
JB was involved in postoperative care of the patient after pancreatic resection, wrote the case report, made literature review and drafted the manuscript. US and CB were the main persons involved in preoperative and diagnostic detection of pancreatic mass and revised the manuscript. MF and AP were involved in diagnosis, adjuvant treatment and follow-up before and after resection of primary tumor and metastasis to the pancreas. Both revised the manuscript. VW performed conventional and immunohistochemical staining of pancreatic ACC metastasis and revised the manuscript. US performed resection of primary tumor and metastasis to the pancreas. Both revised the manuscript. All authors read and approved the final manuscript.

Acknowledgements
This publication was funded by the German Research Foundation (DFG) and the University of Wuerzburg in the funding program Open Access Publishing.

Received: 15 April 2015 Accepted: 20 July 2015
Published online: 31 July 2015

References
1. Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98:4551–64.
2. Fassnacht M, Libe R, Kroiss M, Allolio B. Adrenocortical carcinoma: a clinician’s update. Nat Rev Endocrinol. 2011;7:323–35.
3. Fassnacht M, Johanssen S, Quinkler M, Bucky P, Willenberg HS, Beuschlein F, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer. 2009;115:5847.
4. Remari A, Baudin E, Gelderblom H, Haak HR, Porpiglia F, Fassnacht M, et al. Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7.
5. Else T, Kim AC, Sabolch A, Raymond VM, Kandahl A, Caelli EM, et al. Adrenocortical carcinoma. Endocr Rev. 2014;35:282–326.
6. Fassnacht M, Allolio B. Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab. 2009;23:273–89.
7. Erdogan I, Deutschbein T, Jurowich C, Kroiss M, Ronchi C, Quinkler M, et al. The role of surgery in the management of recurrent adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98:1811–91.
8. Reddy S, Wolfgang CL. The role of surgery in the management of isolated metastases to the pancreas. Lancet Oncol. 2009;10:287–93.
9. Bahra M, Jacob D, Langrehr JM, Glanemann M, Schumacher G, Lopez-Hanninen E, et al. Metastatic lesions to the pancreas. When is resection reasonable? Chirurg. 2008;79:241–8.
10. Crippa S, Angelini C, Mussi C, Bonardi C, Romano F, Santori P, et al. Surgical treatment of metastatic tumors to the pancreas: a single center experience and review of the literature. World J Surg. 2006;30:1536–42.
11. Edid S, Jergas M, Schmidt R, Siedek M. Metastasis to the pancreas—an indication for pancreatic resection? Langenbecks Arch Surg. 2007;392:539–42.
12. Reddy S, Edil BH, Cameron JL, Pawlik TM, Herman JM, Gilson MM, et al. Pancreatic resection of isolated metastases from nonpancreatic primary cancers. Ann Surg Oncol. 2008;15:3199–206.
13. Yuasa T, Inoshita N, Saiura A, Yamamoto S, Urakami S, Masuda H, et al. Clinical outcome of patients with pancreatic metastases from renal cell cancer. BMC Cancer. 2015;15:46.
14. Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Canton PA, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356:2372–80.